We are live on ! Find out more
CARM

Carisma Therapeutics

Delisted

CARM was delisted on the 10th of October, 2025.

51 hedge funds and large institutions have $119M invested in Carisma Therapeutics in 2015 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 10 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 2

40% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 10

24% more funds holding

Funds holding: 4151 (+10)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

21% less capital invested

Capital invested by funds: $151M → $119M (-$32.1M)

Holders
51
Holders Change
+10
Holders Change %
+24.39%
% of All Funds
1.36%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
12
Increased
14
Reduced
10
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SO
51
STRS Ohio
Ohio
-$18.6K -85 Closed
Bank of America
52
Bank of America
North Carolina
+$218 +1 New
Royal Bank of Canada
53
Royal Bank of Canada
Ontario, Canada
+$218 +1 New

CARM Hedge Fund Activity: Q1 2015 in Review

51 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2015, worth a combined $119M — down 21% from $151M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new CARM positions and 2 closed out — a net gain of 10 holders — while 14 added to existing stakes and 10 trimmed.

The largest buyer was Royce & Associates, opening a new position worth an estimated $4.25M. The largest seller was Tekla Capital Management, cutting an estimated $4.53M.

  • 51 institutional investors held Carisma Therapeutics (CARM) as of Q1 2015, up from 41 in Q4 2014.
  • Funds reported $119M of Carisma Therapeutics stock for Q1 2015, down 21% quarter-over-quarter.
  • 12 funds opened new Carisma Therapeutics positions in Q1 2015 and 2 closed out, a net change of +10 holders.
  • The largest Carisma Therapeutics buyer in Q1 2015 was Royce & Associates, an estimated $4.25M added.
  • The largest Carisma Therapeutics seller in Q1 2015 was Tekla Capital Management, an estimated $4.53M sold.

Based on aggregated 13F filings for Q1 2015.